Drug Trial Radar · NCT07730021
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
392
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Feb 28, 2030
Study completion May 31, 2030
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies. The main aims of the study are to check the safety of ASP388B and find the most suitable dose. This study will be in 2 parts. In Part 1, different small groups of people with solid tumors will receive lower to higher doses of ASP388B. Some groups will receive ASP388B by itself, and other groups will receive ASP388B with standard cancer therapies. Any medical problems will be recorded for each dose. This is to find suitable doses of ASP388B to use in Part 2 of the study, and to include the tumor types that responded well to ASP388B. In Part 2, other different small groups of people with the specific tumor types (from Part 1) will receive the most suitable doses worked out from Part 1. Some groups will receive ASP388B by itself, and other groups will receive ASP388B with standard cancer therapies. In both parts of the study, ASP388B will be given once in 3-week cycles. The standard cancer therapies will be given according to their approved label. ASP388B and the standard cancer therapies will be given slowly through a tube into a vein. This is called an infusion. In both parts of the study, health checks will be done at each visit, and the doctors will continue to check for medical problems throughout the study.
Conditions
- Locally Advanced or Metastatic Solid Tumors
Interventions
ASP388BDrug
Intravenous infusion
PembrolizumabDrug
Intravenous infusion
CarboplatinDrug
Intravenous infusion
OxaliplatinDrug
Intravenous infusion
5-fluorouracilDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days after C1D1
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 45 months
- Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 45 months
- Number of participants with vital sign abnormalities and/or AEsTime frame: Up to 45 months
- Number of participants with electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 45 months
- Number of Participants with Physical Examination (PE) abnormalities and/or AEsTime frame: Up to 45 months
- Number of Participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to 45 months
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
START New York
Lake Success, New York · Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.